Laura K. Schnackenberg
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
ARA Fellow
Also affiliated: Universidade Federal de Minas Gerais (2018); University of North Carolina at Chapel Hill (2005); University of Hawaiʻi at Mānoa (2006); United States Department of Health and Human Services (2006); Arkansas Children's Hospital (2009); United States Food and Drug Administration (2006–2025); University of Hawaii System (2006); Suzuki (Japan) (2007); Kangwon National University (2006–2007); Thomas Jefferson National Accelerator Facility (2012); Central Arkansas Veterans Healthcare System (2013); National Cerebral and Cardiovascular Center (2007); Food and Drug Administration (2012); Obihiro University of Agriculture and Veterinary Medicine (2007); Kumamoto University (2007)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Laura K. Schnackenberg's research focuses on toxicology and the development of novel methods for assessing drug-induced toxicity. Her work investigates the mechanisms by which chemical compounds and pharmaceuticals can cause harm, particularly to the liver and kidneys. Schnackenberg has published research on the use of advanced analytical techniques, such as MALDI imaging mass spectrometry and metabolomics, to identify biomarkers of disease and predict patient outcomes. She has also explored the application of in vitro models, including liver-on-a-chip platforms, for studying drug-induced liver injury and evaluating the toxicity of environmental contaminants.
Her research group is actively involved in studying the molecular mechanisms underlying cellular damage, including mitochondrial dysfunction and cell death pathways, in response to drug exposure. Schnackenberg collaborates with researchers at the National Center for Toxicological Research, including Katy S. Papineau and Lijun Ren. Her scholarship metrics include an h-index of 34, with 86 total publications and 3,519 citations. Schnackenberg is recognized as an ARA Fellow and a highly cited researcher in the fields of analytical chemistry and toxicology.
Metrics
- h-index: 34
- Publications: 86
- Citations: 3,533
Selected Publications
-
Balancing efficacy and safety: protein kinase inhibitors and drug-induced liver injury (2026)
-
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)
-
Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids (2025)
-
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury (2022)
-
Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy (2021)
-
Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients (2021)
-
MALDI imaging mass spectrometry: an emerging tool in neurology (2021)
-
Metabolomics Test Materials for Quality Control: A Study of a Urine Materials Suite (2019)
-
Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach (2019)
-
An Integrated Analysis of Metabolites, Peptides, and Inflammation Biomarkers for Assessment of Preanalytical Variability of Human Plasma (2019)
-
An Aptamer‐Based Approach to Assess the Human Plasma Proteome for Pre‐Analytical Variability (2018)
-
Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients (2018)
-
Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans (2017)
ARA Academy 2021 ARA Fellow
Dr. Schnackenberg's work centers on applying advanced analytical chemistry to toxicology and drug safety. From 2003-2019, she focused on NMR metabolomics to evaluate drug toxicity mechanisms. She subsequently adopted MALDI imaging mass spectrometry techniques. As Branch Chief, she directs projects including drug-induced hepatotoxicity biomarker evaluation, patient-specific cell line responses to tyrosine kinase inhibitors, and novel mass spectrometry tools for bacterial and viral identification.
Policy Impact
Directs FDA research programs advancing drug safety evaluation and mass spectrometry tools for pathogen identification, strengthening Arkansas's federal research presence.
Growth Areas
['Population Health Innovations & Clinical Research']
Collaboration Network
Top Collaborators
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- MALDI imaging mass spectrometry: an emerging tool in neurology
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
Similar Researchers
Based on overlapping research topics